The metabolic paradox of aripiprazole: Weight-neutral in monotherapy but weight-reducing as adjunctive therapy

Antipsychotic-induced metabolic dysfunction affects 37–63% of patients, contributing to reduced life expectancy in serious mental illness. Aripiprazole demonstrates a differential effect being weight-neutral in monotherapy but producing substantial weight reduction when combined with clozapine. This...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Madhurima Dhar, Jigyansa Ipsita Pattnaik, Jayaprakash Russell Ravan, Udit Kumar Panda, Pallavi Preetinanda, Sudipta Kumar Das
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wolters Kluwer Medknow Publications 2026-01-01
coleção:	Industrial Psychiatry Journal
Assuntos:	antipsychotic polypharmacy aripiprazole clozapine drug combination therapy metabolic side effects metabolic syndrome psychiatric pharmacotherapy psychopharrmacology treatment-resistant schizophrenia weight reduction
Acesso em linha:	https://journals.lww.com/10.4103/ipj.ipj_213_25
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!